UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________
FORM
__________________________________
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number:
__________________________________
(Exact Name of Registrant as Specified in its Charter)
|
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
|
(Address of Principal Executive Offices) |
(Zip Code) |
(
(Registrant’s Telephone Number, Including Area Code)
Not applicable.
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| None. | None. | None. |
Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)
.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | o | Accelerated filer | o | |
|
|
x | Smaller reporting company |
|
|
| Emerging growth company |
|
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
o
As of November 12, 2025, the registrant had shares of common stock, par value $0.0001 per share, including shares underlying all issued and outstanding Chess Depository Interests (“CDIs”), outstanding.
EBR SYSTEMS, INC.
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025
TABLE OF CONTENTS
PART I — FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EBR SYSTEMS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
|
September 30, 2025 |
December 31, 2024 |
|||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ |
|
$ |
|
||||
| Marketable securities |
|
|
||||||
| Accounts and other receivables, net |
|
|
||||||
| Inventory |
|
|
||||||
| Prepaid expenses |
|
|
||||||
| Other current assets |
|
|
||||||
| Total current assets |
|
|
||||||
| Restricted cash, noncurrent |
|
|||||||
| Property and equipment, net |
|
|
||||||
| Right of use operating lease asset |
|
|
||||||
| Marketable securities |
|
|
||||||
| Inventory, noncurrent |
|
|
||||||
| Other assets |
|
|
||||||
| TOTAL ASSETS | $ |
|
$ |
|
||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ |
|
$ |
|
||||
| Accrued expenses and other liabilities |
|
|
||||||
| Interest payable |
|
|
||||||
| Operating lease liability |
|
|
||||||
| Current portion of notes payable |
|
|||||||
| Total current liabilities |
|
|
||||||
| Other liabilities |
|
|
||||||
| Operating lease liability |
|
|
||||||
| Notes payable, net |
|
|
||||||
| Total liabilities |
|
|
||||||
| Commitments and contingencies (Note 15) | ||||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Common stock, $ par value; shares authorized, and shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively |
|
|
||||||
| Additional paid-in capital |
|
|
||||||
| Accumulated deficit |
(
|
) |
(
|
) | ||||
| Accumulated other comprehensive income |
|
|
||||||
| Total stockholders' equity |
|
|
||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ |
|
$ |
|
||||
These financial statements should be read in connection with the notes to unaudited condensed consolidated financial statements.
| 3 |
EBR SYSTEMS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ |
|
$ | $ |
|
$ | ||||||||||
| Cost of goods sold |
|
|
||||||||||||||
| Gross profit |
|
|
||||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development |
|
|
|
|
||||||||||||
| Selling, general and administrative |
|
|
|
|
||||||||||||
| Total operating expenses |
|
|
|
|
||||||||||||
| Loss from operations |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| Interest income |
|
|
|
|
||||||||||||
| Other income |
|
|
|
|
||||||||||||
| Loss on foreign currency |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| Total other (expense), net |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| Loss before income taxes |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| Income tax benefit (expense) |
|
|
|
|
||||||||||||
| Net loss | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | ||||
| Net loss per share attributable to common stockholders: | ||||||||||||||||
| Basic and diluted | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
| Weighted-average number of common shares outstanding: | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
These financial statements should be read in connection with the notes to unaudited condensed consolidated financial statements.
| 4 |
EBR SYSTEMS, INC.
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net loss | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Change in unrealized gains on marketable securities |
|
|
|
|
||||||||||||
| Foreign currency translation adjustments |
|
|
|
(
|
) | |||||||||||
| Total other comprehensive income |
|
|
|
|
||||||||||||
| Comprehensive loss | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | ||||
These financial statements should be read in connection with the notes to unaudited condensed consolidated financial statements.
| 5 |
EBR SYSTEMS, INC.
Condensed Consolidated Statement of Changes in Stockholders’ Equity
(Unaudited)
| Nine Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||||||
| Total Other | Total | |||||||||||||||||||||||||||||||||||
| Common Stock | Common Stock To Be Issued | Common Stock | Additional | Accumulated | Comprehensive | Stockholders’ | ||||||||||||||||||||||||||||||
| Shares | Par Value | Shares | Amount | Receivable | Paid-in Capital | Deficit | Income | Equity | ||||||||||||||||||||||||||||
| Balance at December 31, 2024 |
|
$ |
|
$ | $ | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||||||
| Exercise of stock options |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Stock-based compensation | - | - |
|
|
||||||||||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Other comprehensive loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Balance at March 31, 2025 |
|
$ |
|
$ | $ | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||||||
| Exercise of stock options |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Stock-based compensation | - | - |
|
|
||||||||||||||||||||||||||||||||
| Issuance of common stock, net of issuance costs |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Other comprehensive loss | - | - |
|
|
||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 |
|
$ |
|
$ | $ | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||||||
| Exercise of stock options |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Stock-based compensation | - | - |
|
|
||||||||||||||||||||||||||||||||
| Issuance costs | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Other comprehensive income | - | - |
|
|
||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 |
|
$ |
|
$ | $ | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||||||
| Nine Months Ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||
| Total Other | Total | |||||||||||||||||||||||||||||||||||
| Common Stock | Common Stock To Be Issued | Common Stock | Additional | Accumulated | Comprehensive | Stockholders’ | ||||||||||||||||||||||||||||||
| Shares | Par Value | Shares | Amount | Receivable | Paid-in Capital | Deficit | Income | Equity | ||||||||||||||||||||||||||||
| Balance at December 31, 2023 |
|
$ |
|
$ | $ | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||||||
| Exercise of stock options |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Stock-based compensation | - | - |
|
|
||||||||||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Other comprehensive loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Balance at March 31, 2024 |
|
$ |
|
$ | $ | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||||||
| Exercise of stock options |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Stock-based compensation | - | - |
|
|
||||||||||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Other comprehensive loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Balance at June 30, 2024 |
|
$ |
|
$ | $ | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||||||
| Exercise of stock options |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Stock-based compensation | - | - |
|
|
||||||||||||||||||||||||||||||||
| Issuance of common stock, net of issuance costs |
|
|
- |
|
|
|||||||||||||||||||||||||||||||
| Common stock receivable in connection with offering, net of issuance costs | - |
|
|
(
|
) | |||||||||||||||||||||||||||||||
| Net loss | - | - |
(
|
) |
(
|
) | ||||||||||||||||||||||||||||||
| Other comprehensive income | - | - |
|
|
||||||||||||||||||||||||||||||||
| Balance at September 30, 2024 |
|
$ |
|
|
$ |
|
$ |
(
|
) | $ |
|
$ |
(
|
) | $ |
|
$ |
|
||||||||||||||||||
These financial statements should be read in connection with the notes to unaudited condensed consolidated financial statements.
| 6 |
EBR SYSTEMS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ |
(
|
) | $ |
(
|
) | ||
| Adjustment to reconcile net loss to cash used in operating activities: | ||||||||
| Depreciation and amortization |
|
|
||||||
| Amortization of deferred loan costs and discount on notes payable |
|
|
||||||
| Lease amortization |
|
|
||||||
| Stock-based compensation |
|
|
||||||
| Loss on disposal of assets |
|
|||||||
| Provision for credit losses |
|
|
||||||
| Accretion of discount on marketable securities |
(
|
) |
(
|
) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts and other receivables |
(
|
) |
|
|||||
| Inventory |
(
|
) | ||||||
| Prepaid expenses |
|
|
||||||
| Other assets |
(
|
) |
(
|
) | ||||
| Accounts payable |
|
|
||||||
| Accrued expenses and other liabilities |
|
(
|
) | |||||
| Interest payable |
(
|
) |
(
|
) | ||||
| Operating lease liability |
|
(
|
) | |||||
| Net cash used in operating activities |
(
|
) |
(
|
) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment |
(
|
) |
(
|
) | ||||
| Purchase of marketable securities |
(
|
) |
(
|
) | ||||
| Maturities of marketable securities |
|
|
||||||
| Sales of marketable securities |
|
|
||||||
| Net cash (used in) provided by investing activities |
(
|
) |
|
|||||
| Cash flows from financing activities: | ||||||||
| Proceeds from notes payable |
|
|||||||
| Repayment of notes payable |
(
|
) |
(
|
) | ||||
| Proceeds from exercise of stock options |
|
|
||||||
| Proceeds from issuance of common stock |
|
|
||||||
| Payment of common stock issuance costs |
(
|
) |
(
|
) | ||||
| Net cash provided by financing activities |
|
|
||||||
| Effect of exchange rate change on cash |
|
(
|
) | |||||
| Net change in cash, cash equivalents, and restricted cash |
|
|
||||||
| Cash, cash equivalents, and restricted cash, beginning of the period |
|
|
||||||
| Cash, cash equivalents, and restricted cash, end of the period | $ |
|
$ |
|
||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest expense | $ |
|
$ |
|
||||
| Cash paid for state income taxes | $ |
|
$ |
|
||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Remeasurement of lease liabilities | $ | $ |
|
|||||
| Common stock to be issued | $ | $ |
|
|||||
| Accrued issuance costs | $ |
|
$ |
|
||||
| Purchases of property and equipment not yet paid | $ |
|
$ | |||||
| Initial recognition of right of use asset and operating lease liability | $ |
|
$ | |||||
These financial statements should be read in connection with the notes to unaudited condensed consolidated financial statements.
| 7 |
EBR SYSTEMS, INC.
Notes to the Unaudited Condensed Consolidated Financial Statements
Note 1 - Business and organization
Business overview
EBR Systems, Inc. and subsidiaries (collectively, “EBR”, “we”, “our” or the “Company”) is a United States based medical device company that developed the WiSE CRT System (“WiSE”), an implantable cardiac device able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads. This implantable device delivers left-ventricle endocardial pacing for cardiac resynchronization therapy (“CRT”), without the use of wires or leads going into the heart. On April 11, 2025, the Company received notification that the U.S. Food and Drug Administration (“FDA”) has completed its review of the premarket approval application (“PMA”) and approved WiSE for commercial distribution in the United States.
The Company completed its initial public offering of CDIs (“CHESS Depositary Interests”) and began trading on the Australian Securities Exchange (“ASX”) on November 24, 2021, under the symbol “EBR”.
The Company operates wholly owned foreign subsidiary entities in Australia, EBR Systems (AUST) Pty Ltd (“EBR-AU”), and the United Kingdom, EBR Systems (UK) Limited (“EBR-UK”), which establish clinical trials in Australia and the United Kingdom, respectively, and work on intellectual property development. EBR-AU was incorporated on February 23, 2017, and EBR-UK was incorporated on July 31, 2015.
Note 2 - Summary of significant accounting policies
Basis of presentation
These unaudited condensed consolidated financial statements as of September 30, 2025, and for the three and nine months ended September 30, 2025 and 2024, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto for the year ended December 31, 2024.
The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the included disclosures are adequate, and the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary for a fair presentation of our unaudited condensed consolidated financial position as of September 30, 2025, unaudited condensed consolidated results of operations and comprehensive loss for the three and nine months ended September 30, 2025 and 2024, and unaudited condensed consolidated cash flows for the nine months ended September 30, 2025 and 2024. The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2025, are not necessarily indicative of the consolidated results of operations that may be expected for the year ending December 31, 2025.
As of and for the three and nine months ended September 30, 2025, the Company changed the presentation of Note 14, “Segment information” to better align with the information the chief operating decision maker (“CODM”) uses to allocate resources and assess operating performance. The change in presentation had no effect on previously reported operating activities. See Note 14 “Segment information” for additional disclosures.
Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant estimates and assumptions made by management include the fair value of stock-based awards issued, capitalized pre-launch inventory, and the valuation allowance on deferred taxes.
| 8 |
Liquidity
The
accompanying unaudited condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles
applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of
business. For the nine months ended September 30, 2025 and 2024, the Company incurred a net loss of $
Fair Value Measurements
The Company measures certain assets and liabilities at fair value, which is defined as the price that would be received from the sale of an asset or paid to transfer a liability on the measurement date in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability. The fair value measurement guidance establishes a fair value hierarchy which requires the Company to maximize the use of observable inputs when measuring fair value. The following levels of inputs may be used to measure fair value:
| · | Level 1: Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. |
| · | Level 2: Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs are observable in active markets are Level 2 valuation techniques. |
| · | Level 3: Valuation techniques in which one or more significant inputs are unobservable. Such inputs reflect our estimate of assumptions that market participants would use to price an asset or liability. |
Foreign currency translation
The functional currencies of our foreign subsidiaries are their local currencies. Accordingly, the Company translates the foreign currency financial statements into US Dollars using the reporting period-end or average exchange rates. Assets and liabilities of these subsidiaries were translated at exchange rates as of the balance sheet dates. Expenses are translated at average rates in effect for the periods presented. The cumulative translation adjustment is included in the accumulated other comprehensive income within stockholders’ equity. Gains and losses arising from the settlement and remeasurement of monetary assets and liabilities denominated in currencies other than the functional currency are included in “loss on foreign currency” in the period in which they occur.
Employee benefits
Employees that satisfy certain eligibility requirements,
including requirements related to age and length of service, are eligible to participate in the EBR Systems, Inc. 401(k) Plan (“Plan”).
The Plan is intended to qualify as a tax-qualified 401(k) plan so that contributions to the Plan, and income earned on such contributions,
are not taxable to participants until withdrawn or distributed from the Plan. Under the Plan, each employee is fully vested in his or
her deferred salary contributions. Employee contributions are held and invested by the plan’s trustee as directed by participants.
Effective January 1, 2025, the Company began a matching contribution under the Plan. The Company matches 100% of employee contributions
to the Plan up to 3% of eligible compensation, with a maximum annual match of $5,000 per employee. Matching contributions vest 25% after
one year of service and are fully vested after two years of service.
For the three
months ended September 30, 2025 and 2024, the Company match expense was $
Cash and cash equivalents
Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash. Cash equivalents are reported at fair value.
| 9 |
Restricted cash
The
restricted cash, noncurrent balance of $
Marketable securities
Marketable securities, all of which are available-for-sale, consist of U.S. treasury bonds, U.S. government notes, and corporate debt securities. Marketable securities are carried at fair value, with unrealized gains and losses reported as accumulated other comprehensive income.
On a quarterly basis, the Company reviews its available-for-sale debt securities for credit-related impairment. An investment security is deemed impaired if the fair value of the investment is less than its amortized cost. For available-for-sale debt securities in an unrealized loss position, the Company evaluates at the individual security level whether the decline in fair value has resulted from credit losses or other factors. In making this assessment the Company considers the issuer of the securities and their creditworthiness, any changes to the rating of the security and any adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance for credit losses is recorded with an offsetting entry to earnings. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income.
The Company typically invests in highly-rated securities and generally limits the amount of credit exposure to any one issuer. Additionally, the Company does not intend to sell the impaired securities, and it is not more likely than not that the Company will be required to sell the investments before recovery of the amortized cost bases. Unrealized losses during the three and nine months ended September 30, 2025 and 2024, were primarily the result of market conditions, such as increasing interest rate movements, unusual market volatility, or industry-related events. Since the fluctuation in fair value is due to changes in market conditions and not credit quality, and because the Company does not intend to sell the investments and it is more likely than not that the Company will not be required to sell the investments before recovery of their amortized cost bases, the Company concluded that an allowance for credit losses was not required as of September 30, 2025.
Interest and dividends on available-for-sale securities are included in other income and expense. See Note 3, “Cash, cash equivalents, restricted cash, and marketable securities” for additional disclosure on marketable securities.
Concentration of credit risk
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are primarily held at U.S. financial institutions that management believes are of high credit quality. Such deposits exceed federally insured limits.
Accounts and other receivables and allowance for credit losses
Trade receivables represent amounts due from customers for the sale of our product. Trade accounts receivable are recorded at the invoiced amount, net of allowances for credit losses for any potential uncollectible amounts. The allowance for credit losses is based on our assessment of the collectability of accounts. Management regularly reviews the adequacy of the allowance for credit losses on a collective basis by considering the age of each outstanding invoice, each customer’s expected ability to pay and collection history, current market conditions, and reasonable and supportable forecasts of future economic conditions to determine whether the allowance is appropriate. Accounts and other receivables are written-off and charged against an allowance for credit losses when the Company has exhausted collection efforts without success.
Non-trade receivables are recorded from amounts due to the Company from contract manufacturers. Unbilled reimbursements represent reimbursement of clinical trial expenses for which reimbursements have not been billed. Reimbursement for leasehold improvements represent allowable costs and fees that will be reimbursed by the landlord in according to the lease agreement. See Note 5, “Condensed consolidated balance sheet components” for additional information on accounts and other receivables.
Inventory
Inventory is comprised of raw materials, work-in-progress and finished goods. Inventory is stated at the lower of cost (determined using the first-in, first-out method) or net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business.
| 10 |
Pre-launch inventory costs associated with products that have not yet received regulatory approval are capitalized if there is probable future commercial use and future economic benefit. If future commercial use and future economic benefit are not considered probable, then costs associated with pre-launch inventory that has not yet received regulatory approval are expensed as research and development expense during the period the costs are incurred. The determination to capitalize is based on the particular facts and circumstances relating to the product. Capitalization of such pre-launch inventory begins when the Company determines that (i) positive clinical trial results have been obtained in order to support regulatory approval is probable; (ii) uncertainties regarding regulatory approval have been significantly reduced; and (iii) it is probable that these capitalized costs will provide future economic benefit, in excess of capitalized costs. Pre-launch inventory was recorded at the lower of cost (determined using the first-in, first-out method) and net realizable value.
On April 11, 2025, the Company received notification from the FDA that WiSE had been approved for commercial distribution in the United States. At that time, the Company began presenting pre-launch inventory as inventory in the unaudited condensed consolidated financial statements and accompanying notes.
Property and equipment
Property and equipment is carried at acquisition cost less accumulated depreciation. The cost of normal, recurring, or periodic repairs and maintenance activities related to property and equipment are expensed as incurred.
Depreciation is computed using the straight-line method based on the estimated useful lives of the related assets. The estimated useful lives by asset classification are generally as follows:
| Equipment |
|
|
| Computer software |
|
|
| Leasehold improvements |
|
Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. For the three and nine months ended September 30, 2025 and 2024, the Company did not recognize any impairment charges associated with long-lived assets.
Leases
At the inception of a contract, the Company determines whether the contract is or contains a lease based on all relevant facts and circumstances. Leases with a term greater than twelve months are recognized on the balance sheet date as right of use (“ROU”) assets and current and noncurrent lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of twelve months or less. The Company includes lease option extensions in the assessment of the lease arrangement when it is reasonably certain the option will be exercised.
Lease liabilities and the corresponding right of use assets are recorded based on the present value of lease payments to be made over the lease term. The discount rate used to calculate the present value is the rate implicit in the lease, or if not readily determinable, the Company’s incremental borrowing rate. The Company’s incremental borrowing rate is the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right of use asset may be required for items such as initial direct costs or incentives received. Lease payments on operating leases are recognized on a straight-line basis over the expected term of the lease. Lease payments on financing leases are recognized using the effective interest method. See Note 6, “Leases” for additional disclosure on leases.
For all asset classes of its leases, the Company has elected to account for the lease and non-lease components together for existing classes of underlying assets
| 11 |
Revenue recognition
In accordance with Accounting Standards Codification 606 Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when control is transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for the goods or services. To recognize revenue, the Company applied the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.
The Company recognizes all of its revenue from contracts with customers at a point in time. As the majority of revenue consists of sales of the WiSE CRT System and battery replacements, where the Company’s sales representative provides assistance at the point of implantation at hospitals or medical facilities, the Company recognizes revenue upon completion of the procedure. The Company also generates a small portion of its revenue from the sale of surgical tool kits. As the performance obligation is the delivery of the product, the Company recognizes revenue for surgical tool kits upon shipment to the customers. For contracts with multiple performance obligations, the total transaction price is allocated to each performance obligation based on the relative standalone selling price. Sales prices are specified in the executed customer contract and purchase order prior to the transfer of control to the customer. The Company’s standard payment terms are generally net 30 days.
The following table summarizes revenue from contracts with customers disaggregated by product for the three and nine months ended September 30, 2025 and 2024:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue: | ||||||||||||||||
| WiSE CRT System | $ |
|
$ | $ |
|
$ | ||||||||||
| Surgical tool kits |
|
|
||||||||||||||
| Battery replacements |
|
|
||||||||||||||
| Total revenue | $ |
|
$ | $ |
|
$ | ||||||||||
Cost of goods sold
The Company purchases components and materials from third-party suppliers and manufacturers. Cost of goods sold consists primarily of costs related to materials, manufacturing overhead costs, reserves for excess, and obsolete and non-sellable inventories. Manufacturing overhead costs includes the cost of material procurement and operations and quality supervision and management personnel, including employee compensation, stock-based compensation, supplies, and travel. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs, such as shipping and handling costs.
Warranty
The Company has a warranty program that offers a warranty on the battery, electrode and transmitter (“Warranty Parts”) of the WiSE for a period of three years commencing on the date of implant. In the event the Warranty Parts function in a manner inconsistent with their intended operation and performance due to the quality of materials or workmanship, and should such an event occur with the three-year period commencing on the implantation date, the Company will provide the customer a replacement at no additional cost. The warranty is not priced or sold separately. It is intended to safeguard the customer against defects, and it does not provide incremental service to the customer. As such, it is considered an assurance type warranty and is not accounted for as a service type warranty, which could represent a separate performance obligation. The warranty is accounted for as an accrued warranty reserve. The current portion is included within “Accrued expenses and other liabilities”, and the long-term portion is included within “Other liabilities” in our unaudited condensed consolidated balance sheets. See Note 5, “Condensed consolidated balance sheet components” for additional disclosure on accrued warranty reserves.
Research and development
Research and development costs are expensed when incurred. Research and development costs include operating expenses for the Company’s engineering and product management functions supporting research, new development, and related product enhancement. Additionally, costs incurred in connection with preclinical development, clinical testing, as well as costs associated with the regulatory and FDA approval process are also included as a component of research and development expense.
| 12 |
Advertising costs
Advertising
costs are expensed as incurred and are included in selling, general and administrative expenses in the unaudited condensed consolidated
statements of operations. During the three and nine months ended September 30, 2025 and 2024, the Company recorded advertising costs of
$
The Company recognizes stock-based compensation expense related to employees over the requisite service period based on the grant-date fair value of the awards. The fair value of options granted is estimated using the Black-Scholes option valuation model. The Company recognizes the grant-date fair value of an award as compensation expense on a straight-line basis over the requisite service period, which typically corresponds to the vesting period for the award. The Company elects to account for forfeitures as they occur and, upon forfeiture of an award prior to vesting, the Company reverses any previously recognized compensation expense related to that award. See Note 11, “Stock-based compensation” for additional details.
Other income
The Company periodically receives reimbursements of clinical trial expenses, which are recorded as other income in the accompanying unaudited condensed consolidated statements of operations. Additionally, other income includes refundable tax incentives from the Australian Taxation Office. Components of Other Income were as follows for the three and nine months ended September 30, 2025, and 2024:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Clinical trial reimbursements | $ | $ |
|
$ | $ |
|
||||||||||
| Research and development tax incentive |
|
|
||||||||||||||
| Total other income | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
Income taxes
The asset and liability approach is used for financial reporting for income taxes. Deferred income balances reflect the effects of temporary differences between the financial reporting and income tax bases of the Company’s assets and liabilities and are measured using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses, or NOLs, and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse.
Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgement including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, and additional information becomes known, or as the tax environment changes.
Basic income or loss per share is determined by dividing net income or loss by the weighted-average common shares outstanding during the period. Diluted income or loss per share is determined by dividing net income by diluted weighted-average shares outstanding during the period. Diluted weighted-average shares reflect the dilutive effect, if any, of potential common shares. To the extent their effect is dilutive, employee equity awards and other commitments to be settled in common stock are included in the calculation of diluted income or loss per share based on the treasury stock method. Potential common shares are excluded from the calculation of dilutive weighted-average shares outstanding if their effect would be anti-dilutive at the balance sheet date based on a treasury stock method or due to a net loss.
| 13 |
Recently issued accounting pronouncements
In December 2023, the FASB issued ASU 2023-09, “ Improvements to Income Tax Disclosures ”. The ASU focuses on income tax disclosures around effective tax rates and cash income taxes paid. ASU 2023-09 is effective for public filers for fiscal years beginning after December 15, 2024. The adoption of ASU 2023-09 will be reflected in the Company’s annual financial statements for the year ending December 31, 2025, and is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses . The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. In January 2025, the FASB issued an update 2025-01 “ Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date”, which revises the effective date of ASU 2024-03 to clarify that all public business entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of this standard on its disclosures.
In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets , which amends ASC 326-20 to provide a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606. The practical expedient permits all entities to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The amendments are effective for annual periods beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance and does not expect a material impact on its financial statements and related disclosures.
In September 2025, the FASB issued ASU 2025-06, " Intangible - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software." This ASU is intended to simplify the capitalization guidance by removing all references to software development project stages and introducing a more judgment-based approach. The amendments in this ASU are effective for fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.
Note 3 – Cash, cash equivalents, and marketable securities
Cash, cash equivalents, and marketable securities consisted of the following as of September 30, 2025 and December 31, 2024:
|
September 30,
2025 |
December 31,
2024 |
|||||||
| Cash and cash equivalents: | ||||||||
| Cash | $ |
|
$ |
|
||||
| Money market funds |
|
|
||||||
| US Treasury securities |
|
|||||||
| Total cash and cash equivalents |
|
|
||||||
| Marketable securities, short-term: | ||||||||
| Asset backed securities |
|
|
||||||
| Commercial paper |
|
|
||||||
| Corporate bonds |
|
|
||||||
| US Treasury securities |
|
|
||||||
| Total marketable securities, short-term |
|
|
||||||
| Marketable securities, long-term: | ||||||||
| Asset backed securities |
|
|
||||||
| Corporate bonds |
|
|||||||
| US Treasury securities |
|
|||||||
| Total marketable securities, long-term |
|
|
||||||
| Total cash, cash equivalents, and marketable securities | $ |
|
$ |
|
||||
| 14 |
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within our unaudited condensed consolidated balance sheets as of September 30, 2025 and September 30, 2024, to the total of such amounts as presented in the unaudited condensed consolidated statements of cash flows:
|
September 30,
2025 |
September 30,
2024 |
|||||||
| Cash and cash equivalents | $ |
|
$ |
|
||||
| Restricted cash, noncurrent |
|
|||||||
| Total cash, cash equivalents, and restricted cash | $ |
|
$ |
|
||||
During the nine months
ended September 30, 2025 and 2024, marketable securities were sold or matured for proceeds of $
The following tables summarize the unrealized gains and losses related to the Company’s available-for-sale marketable securities, by major security type, as of September 30, 2025 and December 31, 2024:
| As of September 30, 2025 | ||||||||||||||||
|
Amortized
Cost |
Unrealized
Gains |
Unrealized
(losses) |
Fair Value | |||||||||||||
| Marketable securities: | ||||||||||||||||
| Asset backed securities | $ |
|
$ |
|
$ |
(
|
) | $ |
|
|||||||
| Commercial paper |
|
|
(
|
) |
|
|||||||||||
| Corporate bonds |
|
|
(
|
) |
|
|||||||||||
| US Treasury securities |
|
|
(
|
) |
|
|||||||||||
| Total marketable securities | $ |
|
$ |
|
$ |
(
|
) | $ |
|
|||||||
| As of December 31, 2024 | ||||||||||||||||
|
Amortized
Cost |
Unrealized
Gains |
Unrealized
(losses) |
Fair Value | |||||||||||||
| Marketable securities: | ||||||||||||||||
| Asset backed securities | $ |
|
$ |
|
$ | $ |
|
|||||||||
| Commercial paper |
|
(
|
) |
|
||||||||||||
| Corporate bonds |
|
|
(
|
) |
|
|||||||||||
| US Treasury securities |
|
|
(
|
) |
|
|||||||||||
| Total marketable securities | $ |
|
$ |
|
$ |
(
|
) | $ |
|
|||||||
The following table shows the unrealized losses and fair values for those marketable securities that were in an unrealized loss position as of September 30, 2025 and December 31, 2024, aggregated by major security type and the length of time the marketable securities have been in a continuous loss position:
| As of September 30, 2025 | ||||||||||||||||||||||||
|
In Loss Position for Less
Than 12 Months |
In Loss Position for 12
Months or Greater |
Total | ||||||||||||||||||||||
| Fair Value |
Unrealized
Losses |
Fair Value |
Unrealized
Losses |
Fair Value |
Unrealized
Losses |
|||||||||||||||||||
| Asset backed securities | $ |
|
$ |
(
|
) | $ | $ | $ |
|
$ |
(
|
) | ||||||||||||
| Commercial paper |
|
(
|
) |
|
(
|
) | ||||||||||||||||||
| Corporate bonds |
|
(
|
) |
|
(
|
) | ||||||||||||||||||
| US Treasury Securities |
|
(
|
) |
|
(
|
) | ||||||||||||||||||
| Total | $ |
|
$ |
(
|
) | $ | $ | $ |
|
$ |
(
|
) | ||||||||||||
| 15 |
| As of December 31, 2024 | ||||||||||||||||||||||||
|
In Loss Position for Less
Than 12 Months |
In Loss Position for 12
Months or Greater |
Total | ||||||||||||||||||||||
| Fair Value |
Unrealized
Losses |
Fair Value |
Unrealized
Losses |
Fair Value |
Unrealized
Losses |
|||||||||||||||||||
| Commercial paper | $ |
|
$ |
(
|
) | $ | $ | $ |
|
$ |
(
|
) | ||||||||||||
| Corporate bonds |
|
(
|
) |
|
(
|
) | ||||||||||||||||||
| US Treasury Securities |
|
(
|
) |
|
(
|
) | ||||||||||||||||||
| Total | $ |
|
$ |
(
|
) | $ | $ | $ |
|
$ |
(
|
) | ||||||||||||
The contractual maturities of the Company’s marketable securities as of September 30, 2025, were as follows:
| Fair Value | ||||
| One year or less | $ |
|
||
| After one year to five years |
|
|||
| Total minimum payments | $ |
|
||
Note 4 – Fair value measurement
Management’s assessment of the significance of a particular input to the fair value measurement requires judgement and may affect the valuation of financial assets and liabilities and their placement within the fair value hierarchy, as discussed in Note 2, “Summary of significant accounting policies”.
As of September 30, 2025 and December 31, 2024, the fair value measurement of the Company’s financial assets measured on a recurring basis were as follows:
| Fair Values as of September 30, 2025 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Cash equivalents: | ||||||||||||||||
| Money market funds | $ |
|
$ | $ | $ |
|
||||||||||
| US Treasury securities |
|
|
||||||||||||||
| Marketable securities: | ||||||||||||||||
| Asset backed securities |
|
|
||||||||||||||
| Commercial paper |
|
|
||||||||||||||
| Corporate bonds |
|
|
||||||||||||||
| US Treasury securities |
|
|
||||||||||||||
| Total | $ |
|
$ |
|
$ | $ |
|
|||||||||
| Fair Values as of December 31, 2024 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Cash equivalents: | ||||||||||||||||
| Money market funds | $ |
|
$ | $ | $ |
|
||||||||||
| Marketable securities: | ||||||||||||||||
| Asset backed securities |
|
|
||||||||||||||
| Commercial paper |
|
|
||||||||||||||
| Corporate bonds |
|
|
||||||||||||||
| US Treasury securities |
|
|
||||||||||||||
| Total | $ |
|
$ |
|
$ | $ |
|
|||||||||
In the Company’s unaudited condensed consolidated balance sheets, the carrying values of accounts and other receivables, other assets, accounts payable and accrued expenses approximated their fair values due to the nature and relatively short maturities. The fair value of debt approximates its carrying value as it is variable rate debt or has relatively short maturities.
| 16 |
Note 5 – Condensed consolidated balance sheet components
Accounts and other receivables, net
Accounts and other receivables includes amounts due from sales of Company’s product to customers, sales of materials to contract manufacturers, reimbursements of clinical trial expenses incurred, and reimbursements for leasehold improvements. Accounts and other receivables, net were as follows as of September 30, 2025 and December 31, 2024:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Trade receivables | $ |
|
$ | |||||
| Non-trade receivables |
|
|
||||||
| Unbilled reimbursements |
|
|||||||
| Reimbursement for leasehold improvements |
|
|||||||
| Accounts and other receivables |
|
|
||||||
| Less: provision for credit losses | ||||||||
| Accounts and other receivables, net | $ |
|
$ |
|
||||
During
the three and nine months ended September 30, 2025, the Company recorded no provision for credit losses. During the three and nine months
ended September 30, 2024, the Company recorded a provision for credit losses $
Inventory
Inventory consisted of the following as of September 30, 2025, and pre-launch inventory consisted of the following at December 31, 2024:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Raw materials | $ |
|
$ |
|
||||
| Work in process |
|
|||||||
| Finished goods |
|
|||||||
| Inventory | $ |
|
$ |
|
||||
| Inventory – current | $ |
|
$ |
|
||||
| Inventory – noncurrent | $ |
|
$ |
|
||||
Property and equipment, net
Property and equipment consisted of the following as of September 30, 2025 and December 31, 2024:
|
September 30,
2025 |
December 31,
2024 |
|||||||
| Equipment | $ |
|
$ |
|
||||
| Computer software |
|
|
||||||
| Leasehold improvements |
|
|
||||||
| Construction in progress |
|
|||||||
| Total property and equipment |
|
|
||||||
| Less accumulated depreciation and amortization |
(
|
) |
(
|
) | ||||
| Total property and equipment, net | $ |
|
$ |
|
||||
As
of September 30, 2025, construction in progress pertains to tenant improvements for the Company’s new corporate headquarters, laboratory,
and manufacturing facility in Santa Clara, California. Depreciation expense for the three months ended September 30, 2025 and 2024 was
$
In
June 2025, the Company retired certain programmer equipment and recorded loss on disposal of fixed assets of $
There
were
| 17 |
Accrued expenses and other liabilities
Accrued expenses and other liabilities consisted of the following as of September 30, 2025 and December 31, 2024:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Accrued compensation and related liabilities | $ |
|
$ |
|
||||
| Accrued development expenses |
|
|
||||||
| Accrued warranty reserves |
|
|
||||||
| Accrued other expenses |
|
|
||||||
| Accrued expenses and other liabilities | $ |
|
$ |
|
||||
Changes in accrued warranty reserves were as follows for the three and nine months ended September 30, 2025 and 2024:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Beginning of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
| Warranty reserve accrued during the period |
|
|
||||||||||||||
| Settlement of warranty claims |
(
|
) |
(
|
) |
(
|
) |
(
|
) | ||||||||
| End of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
| Warranty reserve - current | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
| Warranty reserve - noncurrent | $ |
|
$ | $ |
|
$ | ||||||||||
Note 6 – Leases
The
Company has an operating lease for its corporate headquarters and laboratory space, located in Sunnyvale, California. The initial lease
expired June 30, 2024, with an option to extend the lease an additional sixty-months, which was used in the calculation of the right of
use operating lease asset and operating lease liability. The Company held no other lease agreements at December 31, 2024. In January 2024,
the Company signed an addendum to the operating lease, extending the expiration of the lease through June 30, 2025, and adjusting the
monthly rent from $
In
January 2025, the Company executed an operating lease for its new corporate headquarters, laboratory and manufacturing facility in Santa
Clara, California. The term of the lease commenced on January 17, 2025, the date on which the landlord made the property available to
the Company for the purpose of constructing leasehold improvements that will remain the property of the Company during lease term. As
a result of entering into this lease agreement, the Company recorded a right-of-use asset and corresponding lease liability of $
| 18 |
Amounts reported in the unaudited condensed consolidated balance sheets for operating leases in which the Company is the lessee as of September 30, 2025 and December 31, 2024, were as follows:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Right of use operating lease asset | $ |
|
$ |
|
||||
| Lease liability, current |
|
|
||||||
| Lease liability, noncurrent |
|
|
||||||
| Weighted-average remaining lease term |
|
|
||||||
| Weighted-average discount rate |
|
% |
|
% | ||||
The following table presents the components of lease costs in our unaudited statements of operations for three and nine month ended September 30, 2025 and 2024:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating lease costs | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
| Variable lease costs |
|
|
|
|
||||||||||||
| Short-term lease costs |
|
|
||||||||||||||
| Total lease expense | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
Future lease payments for non-cancellable operating leases, net of the tenant improvement allowance as of September 30, 2025, were as follows:
| Years Ending December 31, | |||||
| 2025 (remaining three months) | $ |
|
|||
| 2026 |
|
||||
| 2027 |
|
||||
| 2028 |
|
||||
| 2029 |
|
||||
| Thereafter |
|
||||
| Total undiscounted lease payments |
|
||||
| Less: effects of discounting |
(
|
) | |||
| Less: tenant improvement allowance |
(
|
) | |||
| Total operating lease liabilities | $ |
|
|||
Note 7 - Notes payable
At September 30, 2025 and December 31, 2024, notes payable consisted of the following:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Notes payable, current | ||||||||
| Current portion of notes payable | $ | $ |
|
|||||
| Notes payable, noncurrent | ||||||||
| Long-term portion of notes payable |
|
|
||||||
| Less: unamortized deferred loan costs |
(
|
) |
(
|
) | ||||
| Less: unamortized discount |
(
|
) |
(
|
) | ||||
| Notes payable, noncurrent, net |
|
|
||||||
| Total notes payable, net | $ |
|
$ |
|
||||
The following table presents information regarding the Company’s notes payable principal repayment obligations as of September 30, 2025:
| Years Ending December 31, | |||||
| 2025 (remaining three months) | $ | ||||
| 2026 | |||||
| 2027 |
|
||||
| Total minimum payments | $ |
|
|||
| 19 |
Runway Growth Finance Corp
On
June 30, 2022, the Company entered into a loan and security agreement with Runway Growth Finance Corp. The debt is secured against substantially
all assets of the Company, except for the Company’s intellectual property but includes all proceeds from the sale of intellectual
property.
As of September 30, 2025 and December 31, 2024, the outstanding principal balance was $
Interest
on the term loan accrues on the principal amount outstanding at a floating per annum rate equal to the greater of the rate of interest
noted in The Wall Street Journal Money Rates section, as the “Prime Rate” or 4.00% plus a margin of 4.9% and is payable monthly
in arrears and shall be computed on the basis of a 360-day year for the actual number of days elapsed. The Company is required to make
interest only payments from July 2022 to May 2027. The note payable has a maturity date of
The
Company has accounted for the final payment of $
The
Company incurred loan costs of $
The Company is subject to customary financial and reporting covenants under the loan and security agreement. As of September 30, 2025 and December 31, 2024, the Company was in compliance with all debt covenants.
Bank of America Leasing & Capital, LLC
In
March 2024, the Company entered into an equipment purchase agreement for the purchase of software totaling $
Note 8 – Preferred stock
As of September 30, 2025 and December 31, 2024, shares of preferred stock were authorized, of which shares were issued or outstanding.
Note 9 – Common stock
Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders
are entitled to receive dividends, as may be declared by the Company’s board of directors. As of September 30, 2025 and December
31, 2024,
As of September 30, 2025 and December 31, 2024, shares were authorized, of which shares and shares, respectively, were outstanding.
The Company completed its initial public offering and began trading on the Australian Securities Exchange (“ASX”) on November 24, 2021, under the symbol “EBR”. The ASX uses an electronic system called CHESS for the clearance and settlement of trades on the ASX. The State of Delaware does not recognize the CHESS system of holding securities or electronic transfers of legal title to shares. To enable companies to have their securities cleared and settled electronically through CHESS, CHESS depository instruments called CDIs are issued. CDIs are units of beneficial ownership in shares and are traded in a manner similar to shares of Australian companies listed on the ASX. The legal title to the shares is held by a depository, CDN, which is a wholly owned subsidiary of the ASX, and is an approved general participant of ASX Settlement.
| 20 |
In
September 2024, the Company completed a fully underwritten institutional placement, and the institutional component of a 1-for-20 pro-rata
accelerated non-renounceable entitlement issuance of
CDIs representing the same number of common stock at $
per
share, for proceeds of $
In
September 2024, the Company announced the retail component of the fully underwritten 1-for-20 pro-rata non-renounceable
entitlement offer of 5,075,733 CDIs representing the same number of common stock. In connection with the entitlement offer,
the Company received a binding commitment from the underwriter to purchase any entitlements not accepted by the Company’s eligible
securityholders. As a result, the Company recognized a common stock receivable of $2,595,864 which was presented as a reduction to
equity in the Company’s unaudited condensed consolidated balance sheets and unaudited condensed consolidated statement of changes
in stockholders’ equity as of September 30, 2024. The Company recorded a corresponding offset of $2,595,864 to common stock
to be issued, a component of equity in the Company’s unaudited condensed consolidated balance sheets and unaudited condensed consolidated
statement of changes in stockholders’ equity as of September 30, 2024. On October 16, 2024, the Company issued
CDIs
at $
per share, and received proceeds of $
In
May 2025, the Company completed an institutional placement of
CDIs representing the same number of common stock at $
per
share, for proceeds of $
Additionally, the Company has reserved the following shares of common stock for issuance as of September 30, 2025:
| Conversion of Common Stock warrants | ||||
| 2013 Equity Incentive Plan | ||||
| Amended 2021 Equity Incentive Plan | ||||
| Outside of Amended 2021 Equity Incentive Plan | ||||
| Total shares of common stock reserved for issuance |
Note 10 – Warrants
Equity classified common stock warrants
The
Company has issued warrants to purchase shares of its common stock, which are exercisable any time at the option of the holder until their
expiration date. As of September 30, 2025 and December 31, 2024, the weighted-average exercise price of outstanding warrants was $
and $
, respectively, with a weighted-average remaining contractual life of
The following warrants were outstanding as of September 30, 2025 and December 31, 2024:
|
Shares of Common Stock Issuable
for Outstanding Warrants as of |
||||||||||||||
| Warrant Issuance |
September 30, 2025 |
December 31, 2024 |
Exercise
Price |
Expiration
Date |
||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
|
|
$ |
|
|
|||||||||||
| Total | ||||||||||||||
| 21 |
The Company and its stockholders adopted an equity incentive plan (the “2013 Plan”) in 2013, which reserved shares of the Company’s common stock for the granting of incentive and nonqualified stock options to employees, directors, and consultants. On October 14, 2021, the Company replaced the 2013 Plan with the 2021 Equity Incentive Plan (“2021 Plan”) in connection with its initial public offering, which was then amended by the Board of Directors and approved by the stockholders on March 18, 2025 and May 21, 2025, respectively. Under the amended 2021 Plan, shares of common stock are reserved. The Company may grant options to purchase common stock, stock appreciation rights, restricted stock awards and other forms of stock-based compensation. Stock options generally vest over four years and expire no later than 10 years from the date of grant. The Board of Directors has the authority to select the employees to whom options are granted and determine the terms of each option, including: i) the number of shares of common stock subject to the option; ii) when the option becomes exercisable; iii) the option exercise price, which must be at least 100% of the fair market value of the common stock as of the date of grant; and iv) the duration of the option, which may not exceed 10 years.
As of September 30, 2025, options to purchase a total of shares of common stock remained outstanding and shares remain available for grant under the amended 2021 Plan and remained outstanding outside of the amended 2021 Plan. As of September 30, 2025, options to purchase a total of shares of common stock remained outstanding under the 2013 Plan. As of September 30, 2025, shares of common stock remain available for grant under the 2013 Plan.
Stock option activity for the nine months ended September 30, 2025, was as follows:
| Shares |
Weighted
Average Exercise Price |
Weighted-
Average Remaining Contractual Life (in years) |
||||||||||
| Outstanding as of December 31, 2024 | $ | |||||||||||
| Granted | ||||||||||||
| Cancelled | ) | |||||||||||
| Exercised | ) | |||||||||||
| Outstanding as of September 30, 2025 | $ | |||||||||||
| Vested and expected to vest as of September 30, 2025 | $ | |||||||||||
| Exercisable as of September 30, 2025 | $ | |||||||||||
The fair value of the options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Company’s common stock, an assumed risk-free interest rate and expected dividends. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatilities of the common stock of several publicly traded entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses the straight-line method for expense attribution. The weighted-average grant-date fair values of stock options granted during the nine months ended September 30, 2025 and 2024, was $ per share and $ per share, respectively.
The following assumptions were used to calculate the grant-date fair value of employee stock options granted during the nine months ended September 30, 2025 and 2024:
| Nine Months Ended September 30, | ||||
| 2025 | 2024 | |||
| Expected term (in years) | - | |||
| Expected volatility | - | - | ||
| Expected dividend yield | ||||
| Risk-free interest rate | - | - | ||
| 22 |
The following table presents classification of stock-based compensation expense within the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2025 and 2024 :
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
As of September 30, 2025, there was $ of unamortized stock-based compensation cost, related to unvested stock options which is expected to be recognized over a weighted-average period of years.
Note 12 – Income taxes
During
the three and nine months ended September 30, 2025 and 2024, the Company does
The
Company’s effective tax rate was
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. These tax law changes do not have a material impact on the Company’s financial statements for the three and nine months ended September 30, 2025.
The following tables sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2025 and 2024:
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Numerator – basic & diluted: | ||||||||||||||||
| Net loss attributable to common stockholders, basic and diluted | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | $ |
(
|
) | ||||
| Denominator: | ||||||||||||||||
| Weighted-average number of shares outstanding, basic and diluted | ||||||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||
The following potentially dilutive shares have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss:
| September 30, | ||||||||
| 2025 | 2024 | |||||||
| Outstanding warrants | ||||||||
| Outstanding stock options | ||||||||
| Total dilutive shares | ||||||||
| 23 |
Note 14 – Segment information
The Company's chief operating decision maker (“CODM”) is the Chief Executive Officer. The Company has determined that it has a single operating and reportable segment. The CODM uses revenue, gross margin and operating expenses at the consolidated level to allocate resources, monitor budget versus actual results, and manage operations. Significant expenses within operating expenses include engineering and development, clinical and regulatory, sales and marketing, and general and administrative expenses at the consolidated level.
Substantially all of the segment revenue is derived from sales to customers in the U.S. Revenue by geography is based on billing address of the customer. International revenue accounted for less than 5% of the total revenue during the periods presented. Long-lived assets held outside the U.S. are immaterial. The following table summarizes the Company's revenue by geography for the three and nine months ended September 30, 2025 and 2024:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| United States | $ |
|
$ | $ |
|
$ | ||||||||||
| International |
|
|
||||||||||||||
| Total Revenue | $ |
|
$ | $ |
|
$ | ||||||||||
The following table disaggregates amounts that comprise research and development, and selling, general and administrative expenses within the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2025 and 2024:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Engineering and development | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
| Clinical and regulatory |
|
|
|
|
||||||||||||
| Total research and development | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
| Sales and marketing | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
| General and administrative |
|
|
|
|
||||||||||||
| Total selling, general and administrative | $ |
|
$ |
|
$ |
|
$ |
|
||||||||
The segment's net loss equals the Company’s net loss as presented in the unaudited condensed consolidated statements of operations. Other segment items within net loss include interest expense, interest income, other income, and loss on foreign currency at the consolidated level.
Note 15 – Commitments and contingencies
Purchase commitments
The
Company
purchases raw materials, manufacturing equipment, and various services from a variety of vendors.
During the normal course of business, in order to manage manufacturing lead times and help ensure an adequate supply of certain items,
we enter into agreements with suppliers that either allow us to procure goods and services when we choose or that establish purchase requirements
over the term of the agreement. In certain instances, our purchase agreements allow us to cancel, reschedule, or adjust our purchase requirements
based on our business needs prior to firm orders being placed. Consequently, only a portion of our purchase commitments are firm and non-cancelable.
As of September 30, 2025, the Company’s obligations
under non-cancelable arrangements
were approximately $
Contingencies
The Company is party to various legal proceedings from time to time. A liability is accrued when a loss is both probable and can be reasonably estimated. Management believes that the probability of a material loss with respect to any currently pending legal proceeding is remote. However, litigation is inherently uncertain, and it is not possible to definitively predict the ultimate disposition of any of these proceedings. The Company does not believe that there are any pending legal proceedings or other loss contingencies that will, either individually or in the aggregate, have a material adverse impact on the Company’s unaudited condensed consolidated financial statements.
| 24 |
Note 16 – Related party transactions
In June 2025, we issued shares of common stock at $ per share in connection with a non-underwritten rights offering to existing stockholders, or Securities Purchase Plan. Dr. Bronwyn Evans, a member of our Board of Directors, participated in the Securities Purchase Plan and purchased CDIs for the aggregate purchase price of $ .
| 25 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes and other information included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2024. In addition to historical data, this discussion contains forward-looking statements about our business, ability to successfully commercialize our WiSE CRT System, results of operations, cash flows, financial condition and prospects based on current expectations that involve risks, uncertainties, assumptions, and other important factors. Our actual results could differ materially from such forward-looking statements. Factors that could cause or contribute to those differences include, but are not limited to, those identified below and those discussed in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K. Additionally, our historical results are not necessarily indicative of the results that may be expected for any period in the future. We use words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," "seek," "should," "will," "would," and similar expressions to identify forward-looking statements.
Overview
EBR is a U.S. based medical device company that developed the WiSE CRT System (“WiSE”), an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads. That implantable device is part of a cardiac resynchronization therapy (“CRT”), offering endocardial heart tissue stimulation without the complications associated with traditional lead-based systems. Cardiac rhythm management (“CRM”) systems use leads to conduct electricity from an implantable pulse generator (“IPG”) to electrodes that deliver therapeutic electric pulses to heart tissue. While leads are a critical part of most CRM systems, they have long been recognized as a primary shortcoming of these systems and are a leading cause of device failure.
We initially developed WiSE for use in conjunction with another implanted pacemaker to provide CRT to patients who are unable to receive CRT from a traditional lead-based system or are at high risk of complications from an upgrade procedure. WiSE CRT technology is engineered to benefit patients who have not seen success with conventional CRT or face high complication risks. By eliminating lead requirements for left ventricular pacing, WiSE CRT introduces a novel approach to cardiac pacing, with the potential to transform CRT delivery.
On April 11, 2025, we received notification that the Center for Devices and Radiological Health (“CDRH”) of the Food and Drug Administration (“FDA”) had completed its review of our premarket approval application (“PMA”) for WiSE and approved WiSE for commercial distribution in the U.S. for adult patients who are at least 22 years of age, are indicated for CRT, have an existing or are eligible for an implanted right ventricular pacing system, and are in one of the following two categories: 1) patients in whom previous coronary sinus (“CS”) lead implantation was unsuccessful, or where an implanted lead has been turned off, referred to as "previously untreatable"; or 2) patients with previously implanted pacemakers or Implantable Cardioverter-Defibrillators (“ICDs”) in whom standard CRT upgrade is not advisable due to known relative contraindications for CS lead or CRT device implantation, referred to as "high risk upgrades".
We have launched WiSE with the focus on driving adoption of WiSE at key, high-volume, hospitals or medical facilities within the U.S. to be followed by select, high-volume hospitals or medical facilities in markets outside the U.S. (“OUS”) that we would target after evaluating regulatory and reimbursement considerations.
| a) | U.S. Strategy |
We have implemented a Limited Market Release (“LMR”), with the following objectives:
LMR objective 1: Initial Target Accounts
| · | Launched in target accounts from the SOLVE-CRT (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy) pivotal trial. |
| · | Leveraged existing relationships with hospitals or medical facilities that participated in previous clinical trials to streamline patient identification and device implantation. |
| 26 |
LMR objective 2: Expansion and Optimization
| · | Strategically expanded our field team to broaden our market presence into additional high-volume hospitals or medical facilities. |
| · | Focused on optimizing the customer training programs and enhancing EBR's business operations. |
LMR objective 3: Increase Implants Per Site
| · | The field team focused on increasing the number of cases per month per hospital or medical facility by improving hospital implant workflows and familiarity with the technology. |
As of September 30, 2025, we have seven active LMR hospitals or medical facilities.
Full Market Release
Our full market release strategy includes the following objectives:
| · | Expand market presence and maximize product adoption. |
| · | Utilize refined business operations and continue scaling the field team. |
| · | Focus on expanding into additional hospitals or medical facilities, leveraging the experience and efficiency gained from the LMR. |
| b) | OUS Strategy |
Our OUS commercial activities will not commence until we obtain regulatory approvals and certification in select, target markets. These initial target markets include Australia, the United Kingdom, and the European Union. The timing of launch in each of these OUS markets thus depends on meeting additional regulatory requirements, as well as on securing the appropriate payment coverage for WiSE in each market.
As a result of its breakthrough device designation (“BDD”), our WiSE CRT technology is eligible for incremental payment coverage in the U.S. for up to three years following FDA approval. The Centers for Medicare & Medicaid Services (“CMS”) has approved of the New Technology Add-On Payment (“NTAP”) for WiSE, commencing October 1, 2025. The NTAP is designed to bridge the financial gap between the costs of innovative technologies and the standard Medicare severity Diagnosis Related Groups (“MS-DRG” or “DRG”) payment structure in place, while encouraging early adoption of the breakthrough medical advancements used in the inpatient setting for Medicare patients. NTAP secures the maximum reimbursement rate of 65% of the cost of WiSE. This is in addition to the DRG payments, which are intended to cover the procedure and the remaining device cost. In June 2025, we received preliminary approval for Transitional Pass-Through (“TPT”) reimbursement scheme of WiSE. Preliminary approval for the TPT reimbursement scheme, will commence October 1, 2025, and is effective for three years. TPT provides hospitals with Medicare reimbursement when treating patients in an outpatient setting. In combination, these reimbursements are intended to fully cover the cost of WiSE in a hospital or outpatient setting.
Financial Overview
Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. Since our inception, our operations have been financed primarily by net proceeds from the sale of our CDIs, common stock, convertible preferred stock, and indebtedness. As of September 30, 2025, we had $73.0 million in cash, cash equivalents, restricted cash, and marketable securities and an accumulated deficit of $388.2 million.
In May 2025, we completed an institutional placement of 55,900,000 CDIs representing the same number of common stock at $0.64 per share, for proceeds of $33,467,662, net of $2,498,398 of related issuance costs. In June 2025, we completed a non-underwritten rights offering to existing stockholders, or Securities Purchase Plan, and issued an additional 20,000,000 CDIs representing the same number of common stock at $0.64 per share, for proceeds of $12,751,318, net of $110,682 of related issuance costs.
| 27 |
Our WiSE CRT System received approval from the FDA for commercial distribution in April 2025, and we began commercializing WiSE during the second quarter of 2025. The commercial potential of and our ability to successfully commercialize WiSE is unproven and will require, among other things, effective sales, marketing, manufacturing, distribution, information systems and pricing strategies, as well as compliance with applicable laws and regulations. Based on our current operating plans and assumptions we believe that our existing cash, cash equivalents, and current and noncurrent marketable securities, together with projected revenue from the U.S of the WiSE CRT System will be sufficient to fund our projected operating requirements for at least the next 12 months from the date of this filing.
Factors Affecting Our Business
There are a number of factors that have impacted, and we believe will continue to impact, our results of operations and growth. These factors include:
| · | Regulatory clearances/post-approval study (“PAS”) . Our business strategy depends on the successful FDA submission of our PAS and ongoing annual reporting of our WiSE CRT System to the FDA. |
| · | Market acceptance . The growth of our business depends on our ability to successfully commercialize WiSE and gain wide acceptance of WiSE by continuing to make physicians and other hospital staff aware of the benefits of WiSE to generate increased demand and frequency of use and thus increase sales to our hospital customers. Our ability to grow our business will also depend on our ability to expand our customer base in existing or new target markets. |
| · | Sales force size and effectiveness . The rate at which we grow our sales force and the speed at which newly hired salespeople become effective can impact our revenue growth or our costs incurred in anticipation of such growth. We intend to make significant investments in our sales and marketing organization by increasing the number of U.S. sales representatives and expanding our international marketing programs to help facilitate further adoption among existing hospital accounts as well as broaden awareness of our products to new hospital accounts. |
| · | Competition . Our industry is intensely competitive and, in particular, we compete with a number of large, well-capitalized companies on multiple fronts. We must strive to be successful in light of our competitors’ existing and future products and related pricing and their resources to successfully market to the physicians who use our products. |
| · | Reimbursement . The level of reimbursement from third-party payors for procedures performed using our products could have a substantial impact on the prices we are able to charge for our products and how widely our products are accepted. The level at which reimbursement is set for procedures using our products, and any increase in reimbursement for procedures using our products, will depend substantially on our ability to generate clinical evidence, to gain advocacy in the respective physician societies and to work with CMS and payors, and to capitalize on the recent CMS approval of our WiSE CRT System for the NTAP, and preliminary approval for TPT reimbursement scheme beginning October 1, 2025. |
| · | Clinical results . Publications of clinical results by us, our competitors and other third parties can have a significant influence on whether, and the degree to which, our products are used by physicians and the procedures and treatments those physicians choose to administer for a given condition. |
While these factors may present significant opportunities for us, they also pose significant risks and challenges that we must address.
Components of our Consolidated Results of Operations
Revenue
We derive most of our revenue from sales of WiSE to the hospital facilities that implant our WiSE CRT System. We recognize revenue upon the transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. Specifically, revenue from the sale of WiSE is recognized at an amount that reflects the expected consideration upon notice that our products have been used in a surgical procedure. Our revenue fluctuates primarily based on the volume of procedures performed. Our revenue is expected to continue to fluctuate in the future from quarter-to-quarter due to a variety of factors, including the success of our sales force in expanding adoption of WiSE in new accounts and the number of physicians who are aware of and implant WiSE.
| 28 |
Nearly all our revenue results from sales in the United States, but we also have limited sales of replacement batteries for our WiSE CRT System to hospital facilities with patients who have been or are currently enrolled in our clinical study in the United Kingdom (“UK”).
Cost of Goods Sold and Gross Margin
Cost of goods sold consists primarily of costs related to materials, components and subassemblies, personnel-related expenses for our manufacturing and quality assurance employees, manufacturing overhead and charges for excess, obsolete and non-sellable inventories. Overhead costs include the cost of quality assurance, testing, material procurement, inventory control, operations supervision and management personnel, an allocation of facilities and information technology expenses, including rent and utilities, and equipment depreciation. Cost of goods sold also includes certain indirect costs such as those incurred for shipping our WiSE CRT System. We record adjustments to our inventory valuation for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions.
We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily by our manufacturing costs, pricing, and the use of inventory that was previously expensed during our clinical trial. Our gross margin is expected to decrease over the near term as we continue to utilize inventory that was previously expensed, but over the long term our gross margin may increase to the extent our production volume increases as our fixed manufacturing costs would be spread over a larger number of units, thereby reducing our per-unit manufacturing costs. We expect our gross margin will fluctuate from period to period, however, based upon the factors described above.
Operating Expenses
Research and Development Expenses
Research and development expenses primarily consist of personnel-related expenses, including salaries, bonuses, fringe benefits and other compensation-related costs, including stock-based compensation expense, for employees engaged in research and development functions. Research and development expenses also include costs of conducting our ongoing clinical studies, such as expenses associated with our clinical research organization, or CRO, who provided project management and other services related to our SOLVE-CRT study, outside service fees paid to third party consultants and contractors related to our product candidate engineering, quality assurance and regulatory approval, as well as contract manufacturing of our product candidate and allocated facility costs.
We expense research and development costs as incurred. Non-refundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and other long-term assets, which are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered.
We anticipate that our research and development expenses will increase in the future as we:
| · | hire and retain additional personnel, including research, clinical, development, quality control, quality assurance and regulatory personnel; |
| · | conduct additional clinical studies beyond our current SOLVE-CRT study; |
| · | continue to advance the research and development of our WiSE CRT system; |
| · | develop, establish, and validate our commercial-scale current good manufacturing practice (“cGMP”). |
Selling, General and Administrative Expenses
Selling, general and administrative expenses primarily consist of personnel-related costs, including salaries, bonuses, fringe benefits and other compensation-related costs, including stock-based compensation expense, for our personnel and external contractors involved in our sales and marketing, executive, finance, legal and other administrative functions, as well as losses on the disposal of property and equipment . Selling, general and administrative expenses also include costs incurred for outside services associated with such functions, including costs associated with obtaining and maintaining our patent portfolio and professional fees for accounting, auditing, tax, legal services, and other consulting expenses.
| 29 |
We anticipate that our selling, general and administrative expenses will increase significantly in the future as we:
| · | hire and retain additional sales, general and administrative personnel to support the expected growth in our sales and marketing activities, research and development activities and the preclinical and clinical development of our product candidates; |
| · | continue to expand our sales, marketing and administrative function to support the sales adoption of WiSE; |
| · | pursue payor coverage and reimbursement for our current and future product candidates; |
| · | maintain, expand, and protect our intellectual property portfolio; and |
| · | incur increased expenses associated with operating as a U.S. publicly reporting company, including increased costs of accounting, audit, legal, regulatory, and tax-related services, and director and officer insurance premiums. |
Other Income (Expenses), net
Interest expense
Interest expense primarily consists of cash and non-cash interest related to our notes payable. See “Loan and Security Agreements” section below for more details about our debt agreements.
Interest income
Interest income consists of interest income, including accretion of discounts, generated from our cash, cash equivalent, and marketable securities.
Other income
Other income includes reimbursements of clinical trial expenses as well as refundable tax incentives from the Australian Taxation Office.
Gain/ (loss) on foreign currency
Gains and losses arising from the settlement and remeasurement of monetary assets and liabilities denominated in currencies other than a subsidiary’s functional currency.
Critical Accounting Estimates
Our critical accounting estimates are more fully described in our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no significant changes to our critical accounting estimates since December 31, 2024, except as discussed below.
Revenue Recognition
In accordance with Accounting Standards Codification 606 Revenue from Contracts with Customers (“ASC 606”), we recognize revenue when control is transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for the goods or services. To recognize revenue, we apply the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.
We recognize all of our revenue from contracts with customers at a point in time. As the majority of revenue consists of sales of WiSE CRT System and battery replacements, where our sales representative provides assistance at the point of implantation at hospitals or medical facilities, we recognize revenue upon completion of the procedure. We also generate a small portion of our revenue from the sale of surgical tool kits that are ordered in advance of a procedure. As the performance obligation is the delivery of the product, we recognize revenue for surgical tool kits upon shipment to the customers. For all performance obligations, the standalone selling price is directly observable as these goods are sold separately by us. Sales prices are specified in the executed customer contract and purchase order prior to the transfer of control to the customer. Our standard payment terms are generally net 30 days.
| 30 |
Recent Accounting Pronouncements
See the section titled “Summary of Significant Accounting Policies—Recently issued accounting pronouncements” in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Non- GAAP Financial Measures
Adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”), a non-GAAP measure used by management to assess operating performance, is defined as net loss, excluding interest expense, net, depreciation and amortization, stock-based compensation, and expenses associated with our Form 10 filling. Adjusted EBITDA is intended as a supplemental measure of our performance and provides useful information to management and investors regarding our operating results.
We present Adjusted EBITDA in this filing because we believe it assists investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our ongoing operating performance. Period-to-period comparison of Adjusted EBITDA helps our management identify additional trends in our Company’s financial results that may not be shown solely by period-to-period comparison of net loss. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to net loss, helps investors make comparisons between our Company and other companies that may have different capital structures, different capitalized asset values, different forms of employee compensation and different strategic nonrecurring projects. Adjusted EBITDA has its limitations as an analytical tool because of the excluded items, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations include:
| · | Adjusted EBITDA does not reflect interest expense and interest income because these items are not directly attributable to the performance of our business operations and may vary over time due to a variety of financing transactions that we have entered into or may enter into in the future. |
| · | Adjusted EBITDA does not reflect certain non-cash items, including depreciation and amortization, and stock-based compensation expense. We believe that excluding the effect of these expenses from Adjusted EBITDA assists management and investors in making period-to-period comparisons in our Company’s operating performance because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. |
| · | Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we do not find indicative of our ongoing operations, such as costs associated with our filing of Form 10-12G. |
A reconciliation between net loss and adjusted EBITDA is presented below:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Reconciliation of net loss to non-GAAP Adjusted EBITDA | ||||||||||||||||
| Net loss | $ | (12,189 | ) | $ | (10,056 | ) | $ | (34,710 | ) | $ | (30,700 | ) | ||||
| Interest expense, net | 607 | 874 | 2,188 | 2,210 | ||||||||||||
| Depreciation and amortization | 90 | 101 | 288 | 497 | ||||||||||||
| Stock-based compensation (a) | 929 | 476 | 2,138 | 1,256 | ||||||||||||
| Expenses associated with Form 10 filling (b) | - | 542 | - | 1,214 | ||||||||||||
| Adjusted EBITDA | $ | (10,563 | ) | $ | (8,063 | ) | $ | (30,096 | ) | $ | (25,523 | ) | ||||
| (a) | Represents non-cash expense associated with our stock-based compensation payments. |
| (b) | Represents nonrecurring expenses associated with our Form 10 filing in 2024. |
| 31 |
Results of Operations
Comparison of the Three Months Ended September 30, 2025, to the Three Months Ended September 30, 2024
We recorded a net loss of $12.2 million in the three months ended September 30, 2025, an increase of $2.1 million, or 21.2%, from the three months ended September 30, 2024. The increased loss in 2025 was due to an increase in selling, general and administrative expenses in 2025, which was partially offset by a decrease in research and development expenses, as discussed below. Other (expense) income, net decreased in 2025 primarily due to an increase in refundable tax incentives, as discussed below.
The following table summarizes our operating results for the three months ended September 30, 2025 and 2024:
|
Three Months Ended
September 30, |
Change | |||||||||||||||
| (in thousands) | 2025 | 2024 | Amount | % | ||||||||||||
| Revenue | $ | 512 | $ | - | $ | 512 | 100.0 | % | ||||||||
| Cost of goods sold | 288 | - | 288 | 100.0 | % | |||||||||||
| Gross profit | 224 | - | 224 | 100.0 | % | |||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 6,244 | 6,298 | (54 | ) | (0.9 | %) | ||||||||||
| Selling, general and administrative | 5,861 | 2,879 | 2,982 | 103.6 | % | |||||||||||
| Total operating expenses | 12,105 | 9,177 | 2,928 | 31.9 | % | |||||||||||
| Other (expense) income, net | (308 | ) | (879 | ) | 571 | (65.0 | %) | |||||||||
| Loss before income tax | (12,189 | ) | (10,056 | ) | (2,133 | ) | 21.2 | % | ||||||||
| Income tax expense | - | - | - | - | ||||||||||||
| Net Loss | $ | (12,189 | ) | $ | (10,056 | ) | $ | (2,133 | ) | 21.2 | % | |||||
We derive the majority of our revenue from sales to customers in the United States. International revenue is attributable to the battery replacements for clinical trial patients in the UK. Revenue by geography is based on the billing address of the customer. The table below summarizes our revenue by geography:
| Three Months Ended | Three Months Ended | |||||||||||||||
| September 30, 2025 | September 30, 2024 | |||||||||||||||
| (in thousands) | Amount | % | Amount | % | ||||||||||||
| United States | $ | 509 | 99.4 | % | $ | - | - | |||||||||
| International | 3 | 0.6 | % | - | - | |||||||||||
| Total Revenue | $ | 512 | 100.0 | % | $ | - | - | |||||||||
Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin:
|
Three Months Ended
September 30, |
Change | |||||||||||||||
| (in thousands) | 2025 | 2024 | Amount | % | ||||||||||||
| Revenue | $ | 512 | $ | - | $ | 512 | 100.0 | % | ||||||||
| Cost of goods sold | 288 | - | 288 | 100.0 | % | |||||||||||
| Gross profit | $ | 224 | $ | - | $ | 224 | 100.0 | % | ||||||||
| Gross margin | 43.8 | % | - | 43.8 | % | 100.0 | % | |||||||||
Revenue and Cost of Goods Sold
Revenue and cost of goods sold increased to $0.5 million and $0.3 million, respectively, or 100%, during the three months ended September 30, 2025, as compared to the three months ended September 30, 2024, resulting from the FDA approval of our WiSE CRT System in April 2025. During the three months ended September 30, 2025, we had commercial implants at four incrementally new hospitals in the US.
| 32 |
Gross Profit, and Gross Margin
Gross profit increased to $0.2 million, or 100% for the three months ended September 30, 2025, as compared to the three months ended September 30, 2024, resulting from the FDA approval of our WiSE CRT System in April 2025. Gross margin was 43.8% for the three months ended September 30, 2025. Our gross margin was positively affected and will continue to be affected in the near future by the use of inventory that was previously expensed during our clinical trial. Excluding the use of previously expensed inventory, we would have had a negative gross margin of 25.3%.
Operating Expenses
Research and Development
The following table presents our total research and development expenses by category:
|
Three Months Ended
September 30, |
Change | |||||||||||||||
| (in thousands) | 2025 | 2024 | Amount | % | ||||||||||||
| Research and development expenses: | ||||||||||||||||
| R&D personnel expense | $ | 4,981 | $ | 4,491 | $ | 490 | 10.9 | % | ||||||||
| Clinical expenses | 599 | 429 | 170 | 39.6 | % | |||||||||||
| Quality assurance | 103 | 61 | 42 | 68.9 | % | |||||||||||
| Contract manufacturing, materials & components | 484 | 935 | (451 | ) | (48.2 | %) | ||||||||||
| Facility allocation & depreciation | 77 | 382 | (305 | ) | (79.8 | %) | ||||||||||
| Total research and development expense | $ | 6,244 | $ | 6,298 | $ | (54 | ) | (0.9 | %) | |||||||
Research and development expenses decreased by $0.1 million, or 0.9%, during the three months ended September 30, 2025, as compared to the three months ended September 30, 2024. The decrease was primarily due to a $0.5 million decrease in contract manufacturing, materials and components, resulting from a decrease in professional services related to the development testing of WiSE, as well as capitalization of inventory. Facility-related expenses decreased by $0.3 million, as we capitalized certain overhead costs to inventory during the three months ended September 30, 2025. These decreases were partially offset by a $0.5 million increase in personnel-related expenses, including salaries, bonuses, and certain fringe benefits, resulting from workforce expansion, and a $0.2 million increase in clinical trial expenses.
Selling, General and Administrative Expenses
Selling, General and administrative expenses increased by $3.0 million, or 103.6%, during the three months ended September 30, 2025, as compared to the three months ended September 30, 2024. Personnel-related expenses including salaries, bonuses, stock-based compensation and certain fringe benefits increased by $2.3 million as a result of the expansion of our workforce to support our sales and marketing efforts after the FDA approval of WiSE. Travel-related expenses increased by $0.6 million due the expansion of our workforce to support our sales and marketing efforts. Facility-related expenses increased by $0.1 million, primarily resulting from the higher non-cash rent expense due to a new lease agreement entered in 2025.
Other (expense) income, net
Other (expense) income, net decreased by $0.6 million during the three months ended September 30, 2025, as compared to the three months ended September 30, 2024. Other income has increased by $0.3 million, primarily resulting from an increase in refundable tax incentives. Interest expense decreased by $0.1 million, and interest income earned on investments in marketable securities, including the accretion of discounts on marketable securities has increased by $0.2 million.
Comparison of the Nine Months Ended September 30, 2025, to the Nine Months Ended September 30, 2024
We recorded a net loss of $34.7 million in the nine months ended September 30, 2025, an increase of $4.0 million, or 13.1%, from the nine months ended September 30, 2024. The increased loss in 2025 was due to an increase in selling, general and administrative expenses in 2025, which was partially offset by a decrease in research and development expenses, as discussed below. Other (expense) income, net also decreased in 2025 primarily due to an increase in refundable tax incentives and decrease in interest expense, as discussed below.
| 33 |
The following table summarizes our operating results for the nine months ended September 30, 2025 and 2024:
|
Nine Months Ended
September 30, |
Change | |||||||||||||||
| (in thousands) | 2025 | 2024 | Amount | % | ||||||||||||
| Revenue | $ | 682 | $ | - | $ | 682 | 100.0 | % | ||||||||
| Cost of goods sold | 374 | - | 374 | 100.0 | % | |||||||||||
| Gross profit | 308 | - | 308 | 100.0 | % | |||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 17,614 | 20,171 | (2,557 | ) | (12.7 | %) | ||||||||||
| Selling, general and administrative | 15,488 | 8,322 | 7,166 | 86.1 | % | |||||||||||
| Total operating expenses | 33,102 | 28,493 | 4,609 | 16.2 | % | |||||||||||
| Other (expense) income, net | (1,916 | ) | (2,207 | ) | 291 | (13.2 | %) | |||||||||
| Loss before income tax | (34,710 | ) | (30,700 | ) | (4,010 | ) | 13.1 | % | ||||||||
| Income tax expense | - | - | - | - | ||||||||||||
| Net Loss | $ | (34,710 | ) | $ | (30,700 | ) | $ | (4,010 | ) | 13.1 | % | |||||
We derive the majority of our revenue from sales to customers in the United States. International revenue is attributable to the battery replacements for clinical trial patients in the UK. Revenue by geography is based on the billing address of the customer. The table below summarizes our revenue by geography:
| Nine Months Ended | Nine Months Ended | |||||||||||||||
| September 30, 2025 | September 30, 2024 | |||||||||||||||
| (in thousands) | Amount | % | Amount | % | ||||||||||||
| United States | $ | 658 | 96.5 | % | $ | - | - | |||||||||
| International | 24 | 3.5 | % | - | - | |||||||||||
| Total Revenue | $ | 682 | $ | 100 | % | $ | - | - | ||||||||
Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin:
|
Nine Months Ended
September 30, |
Change | |||||||||||||||
| (in thousands) | 2025 | 2024 | Amount | % | ||||||||||||
| Revenue | $ | 682 | $ | - | $ | 682 | 100.0 | % | ||||||||
| Cost of goods sold | 374 | - | 374 | 100.0 | % | |||||||||||
| Gross profit | $ | 308 | $ | - | $ | 308 | 100.0 | % | ||||||||
| Gross margin | 45.2 | % | - | 45.2 | % | 100.0 | % | |||||||||
Revenue and Cost of Goods Sold
Revenue and cost of goods sold increased to $0.7 million and $0.4 million, respectively, or 100%, during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024, resulting from the FDA approval of our WiSE CRT System in April 2025. During the nine months ended September 30, 2025, we had commercial implants at seven hospitals in the US.
Gross Profit, and Gross Margin
Gross profit increased to $0.3 million, or 100% for the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024, resulting from the FDA approval of our WiSE CRT System in April 2025. Gross margin was 45.2% for the nine months ended September 30, 2025. Our gross margin was positively affected and will continue to be affected in the near future by the use of inventory that was previously expensed during our clinical trials. Excluding the use of previously expensed inventory, we would have had a negative gross margin of 31.9%.
| 34 |
Operating Expenses
Research and Development
The following table presents our total research and development expenses by category:
|
Nine Months Ended
September 30, |
Change | |||||||||||||||
| (in thousands) | 2025 | 2024 | Amount | % | ||||||||||||
| Research and development expenses: | ||||||||||||||||
| R&D personnel expense | $ | 13,829 | $ | 12,784 | $ | 1,045 | 8.2 | % | ||||||||
| Clinical expenses | 1,560 | 1,266 | 294 | 23.2 | % | |||||||||||
| Quality assurance | 273 | 185 | 88 | 47.6 | % | |||||||||||
| Contract manufacturing, materials & components | 1,744 | 4,659 | (2,915 | ) | (62.6 | %) | ||||||||||
| Facility allocation & depreciation | 208 | 1,277 | (1,069 | ) | (83.7 | %) | ||||||||||
| Total research and development expense | $ | 17,614 | $ | 20,171 | $ | (2,557 | ) | (12.7 | %) | |||||||
Research and development expenses decreased by $2.6 million, or 12.7%, during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024. The decrease was primarily due to a $2.9 million decrease in contract manufacturing, materials and components, resulting from a decrease in professional services related to the development testing of the WiSE CRT System, as well as capitalization of inventory. Facility-related expenses decreased by $1.1 million, as we capitalized certain overhead costs to inventory during the nine months ended September 30, 2025. These decreases were partially offset by a $1.0 million increase in personnel-related expenses, including salaries, bonuses, and certain fringe benefits, resulting from the normal annual salary increases and workforce expansion, and a $0.3 million increase in clinical expenses.
Selling, General and Administrative Expenses
Selling, General and administrative expenses increased by $7.2 million, or 86.1%, during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024. Personnel-related expenses including salaries, bonuses, stock-based compensation and certain fringe benefits increased by $5.2 million as a result of the expansion of our workforce to support increased adoption of our WiSE CRT System. Facility-related and other expenses increased by $0.4 million, primarily resulting from the higher non-cash rent expense due to a new lease agreement entered in 2025. Travel-related expenses increased by $1.2 million due the expansion of our workforce to support our sales and marketing efforts. Corporate expenses increased by $0.4 million, primarily resulting from the higher expenses related to insurance premiums, investor relations, and computer software.
Other (expense) income, net
Other (expense) income, net decreased by $0.3 million during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024. Other income increased by $0.3 million, primarily resulting from an increase in refundable tax incentives, and interest expense decreased by $0.3 million. These changes were partially offset by a $0.3 million decrease in interest income earned on investments in marketable securities, including the accretion of discounts on marketable securities.
Liquidity and Capital Resources
We believe that our cash and cash equivalents, and marketable securities, and anticipated revenues from sales of our WiSE CRT System will be sufficient to fund our operations for at least the next 12 months from the date of this filing. We manage our cash and capital structure to maximize shareholder return, maintain its financial condition and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, debt maturity schedule, capital expenditure requirements and future investments. As of September 30, 2025 and December 31, 2024, we had approximately $70.4 million and $66.0 million, respectively, in cash, cash equivalents, and marketable securities. In the long-term, our ability to support our working capital and capital expenditure requirements will depend on many factors, including:
| · | our ability to successfully commercialize our WiSE CRT System; |
| 35 |
| · | the cost, timing and results of our clinical trials and regulatory reviews; |
| · | the cost of our research and development activities for new and modified products; |
| · | the cost and timing of establishing sales, marketing and distribution capabilities; |
| · | the terms and timing of other collaborative, licensing and other arrangements that may establish including any contract manufacturing arrangements; |
| · | the timing, receipt and amount of sales from our current and potential products; |
| · | the degree of success we experience in sales and marketing activities our products; |
| · | the emergence of competing or complementary technologies; |
| · | the impact of global business, political and macroeconomic conditions, including inflation, rising interest rates, uncertainty with respect to the federal budget, instability in the global banking system, volatile market conditions, supply chain disruptions, cybersecurity events, and global events, including regional conflicts around the world; |
| · | the cost of preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights; and |
| · | the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions. |
To the extent that current and anticipated future sources of liquidity are insufficient to fund our future business activities and cash and other requirements, we may be required to seek additional equity or debt financing. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of additional debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. In the event that additional financing is required from outside sources, there is a possibility we may not be able to raise it on terms acceptable to us or at all. Further, the current macroeconomic environment may make it difficult for us to raise capital on terms favorable to us or at all. If we are unable to raise additional capital when desired, our business, operating results, and financial condition could be adversely affected.
Loan and Security Agreements
On June 30, 2022, we entered into a loan and security agreement with Runway Growth Finance Corp. The debt is secured against substantially all of our assets, except for intellectual property, but includes all proceeds from the sale of intellectual property.
As of September 30, 2025 and December 31, 2024, the outstanding principal balance was $41,800,000, which includes final payment of 4.5% of the principal borrowings to date.
Interest on the term loan accrues on the principal amount outstanding at a floating per annum rate equal to the greater of the rate of interest noted in The Wall Street Journal Money Rates section, as the “Prime Rate” or 4.00% plus a margin of 4.9% and is payable monthly in arrears and shall be computed on the basis of a 360-day year for the actual number of days elapsed. We are required to make interest only payments from July 2022 to May 2027. The note payable has a maturity date of June 15, 2027, at which time any unpaid interest, outstanding principal balance, and a final payment of 4.5% of the original principal amount borrowed shall be due in full. If we repay the loan prior to maturity, we will be required to pay a prepayment fee of 0.5% - 1% of the outstanding principal balance. We are also required to pay a 3% success fee of the funded principal amount of the term loan at the time of a liquidity event, as defined in the loan and security agreement. The success fee is enforceable within 10 years from the execution date of the agreement.
We are subject to customary financial and reporting covenants under the loan and security agreement. As of September 30, 2025 and December 31, 2024, we were in compliance with all debt covenants.
Recent Financings
In May 2025, we completed an institutional placement of 55,900,000 CDIs representing the same number of common stock at $0.64 per share, for proceeds of $33,467,662, net of $2,498,398 of related issuance costs. In June 2025, we completed a non-underwritten rights offering to existing stockholders, or Securities Purchase Plan, and issued an additional 20,000,000 CDIs representing the same number of common stock at $0.64 per share, for proceeds of $12,751,318, net of $110,682 of related issuance costs.
| 36 |
Contractual Obligations and Commitments
As of September 30, 2025, we had $0.7 million in operating lease obligations for our corporate headquarters and laboratory space located in Sunnyvale, California. Additionally, in January 2025, we entered into a new lease agreement for our new corporate headquarters, laboratory and manufacturing facility in Santa Clara, California, for which we had recorded $15.4 million in operating lease obligations as of September 30, 2025.
As of September 30, 2025, the outstanding principal balance under our loan and security agreement described above was $41,800,000, which includes the final payment of 4.5% of the principal borrowings to date.
In addition, we enter into contracts in the normal course of business with third-party contract organizations for clinical trials, manufacturing and other services and products for operating purposes. In certain instances, our purchase agreements allow us to cancel, reschedule, or adjust our purchase requirements based on our business needs prior to firm orders being placed. Consequently, only a portion of our purchase commitments are firm and non-cancelable. As of September 30, 2025, our obligations under non-cancelable arrangements were approximately $12.1 million.
Working Capital
September 30, 2025, Compared to December 31, 2024
As of September 30, 2025, we had working capital of $71.9 million, comprised of current assets of $82.2 million and current liabilities of $10.3 million. Current assets, consisting of cash and cash equivalents, marketable securities, accounts and other receivables, inventory, prepaid expenses, and other current assets, increased by $17.8 million as of September 30, 2025, compared to December 31, 2024. The sale of CDIs discussed above contributed to the overall increase in cash, cash equivalents and marketable securities, resulting in a $7.7 million increase in working capital as of September 30, 2025. Additionally, the capitalization of inventory resulted in a $8.3 million increase in working capital, and an increase in the accounts and other receivables primarily due to the reimbursements for leasehold improvements resulted in a $2.3 million increase in working capital as of September 30, 2025. Current liabilities, consisting primarily of accounts payable, accrued liabilities, lease obligations, and interest payable, increased by approximately $2.0 million as of September 30, 2025, compared to December 31, 2024. The increase primarily resulted from a $1.3 million increase in accounts payable, which was mainly due to the activity related to construction of leasehold improvements at the new corporate headquarters, as well as the purchases of raw materials. The abovementioned construction of leasehold improvements also resulted in a $0.2 million increase in accrued expenses due to increase in retainage that will be payable upon the project completion. Additionally, the execution of a new lease agreement in 2025 resulted in $0.5 million increase in operating lease liabilities, which contributed to the overall increase in current liabilities.
Cash Flows
September 30, 2025, Compared to September 30, 2024
The following table summarizes our cash flows for the nine months ended September 30, 2025 and 2024:
| Nine Months Ended September 30, | ||||||||
| (in thousands) | 2025 | 2024 | ||||||
| Net cash used in operating activities | $ | (38,181 | ) | $ | (30,243 | ) | ||
| Net cash (used in) provided by investing activities | (281 | ) | 22,284 | |||||
| Net cash provided by financing activities | 46,772 | 29,802 | ||||||
| Effect of exchange rate change on cash | 18 | (11 | ) | |||||
| Net change in cash, cash equivalents and restricted cash | $ | 8,328 | $ | 21,832 | ||||
| 37 |
Operating Activities
Net cash used in operating activities during the nine months ended September 30, 2025, was $38.1 million, compared to $30.2 million during the nine months ended September 30, 2024, representing an increase in use of $7.9 million. This increase is primarily attributed to an increase in net loss of $4.0 million and an increase in use of cash from changes in working capital of $6.0 million, which were partially offset by an increase in non-cash adjustments of $2.1 million.
| · | The increase in net loss of $4.0 million primarily resulted from an increase in personnel costs, which was partially offset by a decrease in contract manufacturing, materials and components, as further described under “Results of Operations” above. |
| · | Non-cash adjustments increased due to decrease in gain in accretion of discount on marketable securities of $0.8 million driven by fluctuating interest rates and maturity term, $0.6 million increase in the adjustment to lease amortization due to the Company entering into a new lease agreement in 2025, and $0.9 million increases in stock-based compensation due to new options issuance to new hires and existing employees. These increases were partially offset by a $0.2 million decrease in depreciation and amortization due to assets that have been fully depreciated. |
| · | The decrease in changes from working capital activities primarily consisted of $7.1 million use of cash for inventory purchases, a $2.4 million decrease in cash provided from accounts and other receivables primarily due to the timing of collections on reimbursable leasehold improvements, and a $0.2 million increase in use of cash for deposits to vendors. These decreases were partially offset by a $2.4 million increase in the operating lease liability due to the reimbursement of tenant improvements and the amortization of the right of use operating lease asset, and a $1.3 million increase in cash provided from accounts payable and accrued expenses due to the timing of invoice payments. |
Investing Activities
Net cash used in investing activities during the nine months ended September 30, 2025, was $0.3 million, compared to $22.3 million net cash provided during the nine months ended September 30,2024, representing an increase in cash used of $22.6 million. The increase was attributable to a $18.2 million increase in the purchase of marketable securities, a $2.0 million increase in cash used for purchases of property and equipment, and a $2.4 million net decrease in cash provided from the maturities and sales of marketable securities during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024.
Financing Activities
Net cash provided by financing activities during the nine months ended September 30, 2025 was $46.8 million, compared to $29.8 million during the nine months ended September 30, 2024, representing an increase of $17.0 million. This increase was primarily attributed to the $16.7 million increase in proceeds from a capital raise, net of issuance cost, during the nine months ended September 30, 2025, as well as by a $0.4 million increase in proceeds from exercise of stock options. These increases were partially offset by $0.1 million decrease in proceeds from borrowings on notes payable during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024.
ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information specified under this item.
ITEM 4: CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15(d)-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2025.
| 38 |
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the three months ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating disclosure controls and procedures, our management recognizes that any system of controls, however well designed and operated, can provide only reasonable assurance, and not absolute assurance, that the desired control objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals in all future circumstances. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and our Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this quarterly report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.
PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
ITEM 1A. RISK FACTORS
In addition to other information set forth in this report, readers should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" of our 2024 Annual Report on Form 10-K, as updated and supplemented below. Any of the risk factors disclosed in our reports could materially affect our business, financial condition or future results. The risks described here and in our 2024 Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results. The discussion of the risk factors below updates the corresponding disclosure under the same heading in the 2024 Annual Report on Form 10-K and may contain material changes to the corresponding risk factor discussion in our 2024 Annual Report on Form 10-K.
We are subject to ongoing FDA post-marketing obligations concerning our WiSE CRT System, which may result in significant additional expense, and we may be subject to penalties or product withdrawal if we fail to comply with these regulatory requirements and commitments or if we experience unanticipated regulatory issues with WiSE CRT System.
Our WiSE CRT System’s regulatory approval in the United States is subject to certain post-marketing obligations and commitments to the FDA. We are required to conduct a prospective, real-world, observational study aimed at understanding acute and long-term product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market released WiSE. We expect to begin enrollment for this post-marketing study in November 2025, and it is scheduled to be concluded in December 2027. Participants enrolled in the study will be monitored at one month, six month, and annual follow-up visits for up to five years post implant. Failure to meet enrollment requirements or complete the study to the satisfaction of the FDA could result in withdrawal of WiSE’s application approval, which would have a material adverse effect on our business, results of operations, financial condition and prospects. The results of the post-marketing study may also result in additional warnings or precautions for the WiSE CRT System label, or expose additional safety concerns that may result in product liability, reputational damage with physicians and/or withdrawal of the product from the market, any of which would have a material adverse effect on our business, results of operations, financial condition and prospects.
| 39 |
In addition, the manufacturing processes, labelling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for WiSE are subject to extensive and ongoing regulatory requirements in the United States. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices (“cGMP”), good clinical practices (“GCP”), and good laboratory practices ( “GLP” ) . If we are not able to meet and maintain regulatory compliance for WiSE, we may lose marketing approval and be required to withdraw our product. Withdrawal of our product would have a material adverse effect on our business.
Changes in economic conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business, operations, and financial condition.
Our operations and performance are impacted by global, regional and U.S. economic and geopolitical conditions. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty. The U.S. government has recently announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the medical device industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. These developments have created a dynamic and unpredictable trade landscape, which may adversely impact our business, results of operations, financial condition and prospects.
The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt non-tariff measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit our ability to attract non-U.S. investment, employees, customers, and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased enforcement actions, or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our business.
Trade disputes, tariffs, restrictions and other political tensions between the United States and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn, escalation in trade tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial condition, and prospects. In addition, tariffs and other trade developments have and may continue to heighten the risks related to other risk factors described in our 2024 Annual Report on Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
| 40 |
ITEM 5. OTHER INFORMATION
During the three months ended September 30, 2025,
none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)
| 41 |
ITEM 6. EXHIBITS
The following exhibits are filed or furnished as part of this report:
* Filed herewith
# In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management's Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purpose of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.
| 42 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| EBR SYSTEMS, INC. | |||
| By: | /s/John McCutcheon | ||
| Name: | John McCutcheon | ||
| Title: |
Chief Executive Officer (Principal Executive Officer) |
||
| By: | /s/Gary Doherty | ||
| Name: | Gary Doherty | ||
| Title: |
Chief Financial Officer (Principal Financial and Accounting Officer) |
||
Date: November 12, 2025
43